CAJ | 학술논문

目的：观察咳喘宁胶囊对慢性阻塞性肺疾病(COPD)稳定期患者气道炎症细胞及炎性介质的影响。方法采用随机数字表法将110例COPD稳定期患者随机分为治疗组和对照组各55例。2组均予复方异丙托溴铵溶液气雾吸入。同时，治疗组口服咳喘宁胶囊，每次4粒，每日3次；对照组口服等剂量安慰剂胶囊。疗程均为3个月。观察痰炎症细胞分类计数、血清及痰上清液中炎症因子水平。结果治疗组治疗后痰中性粒细胞下降(P＜0.05)、巨噬细胞增多(P＜0.05)，与对照组比较差异有统计学意义(P＜0.05)。2组治疗前后血清白细胞介素(IL)-6、IL-8、白三烯B4(LTB4)水平差异无统计学意义(P＞0.05)；治疗组治疗后痰上清液IL-6、IL-8、LTB4水平均下降(P＜0.05)，与对照组比较差异有统计学意义(P＜0.05)。结论咳喘宁胶囊对稳定期 COPD 患者气道炎症细胞及炎性介质释放有明显的抑制作用。
목적：관찰해천저효낭대만성조새성폐질병(COPD)은정기환자기도염증세포급염성개질적영향。방법채용수궤수자표법장110례COPD은정기환자수궤분위치료조화대조조각55례。2조균여복방이병탁추안용액기무흡입。동시，치료조구복해천저효낭，매차4립，매일3차；대조조구복등제량안위제효낭。료정균위3개월。관찰담염증세포분류계수、혈청급담상청액중염증인자수평。결과치료조치료후담중성립세포하강(P＜0.05)、거서세포증다(P＜0.05)，여대조조비교차이유통계학의의(P＜0.05)。2조치료전후혈청백세포개소(IL)-6、IL-8、백삼희B4(LTB4)수평차이무통계학의의(P＞0.05)；치료조치료후담상청액IL-6、IL-8、LTB4수평균하강(P＜0.05)，여대조조비교차이유통계학의의(P＜0.05)。결론해천저효낭대은정기 COPD 환자기도염증세포급염성개질석방유명현적억제작용。
Objective To observe the effects of Kechuanning capsules on airway inflammation cells and inflammatory mediators in patients with COPD.Methods Totally 110 patients with stable COPD were randomly divided into therapy group and control group, 55 cases in each group. Both of the groups were given compound ipratropium bromide solution for inhalation, at the same time, patients in the therapy group took Kechuanning capsules orally, 4 softgels each time, 3 times a day, and patients in the control group took the same amount of placebo capsules. The treatment lasted three months. Differential counting of inflammatory cells and levels of inflammatory factors in serum and sputum supernatant were observed.Results In terms of differential counting of inflammatory cells, the sputum neutrophils of the therapy group decreased significantly (P<0.05) and macrophages increased (P<0.05) after treatment, with statistical significance compared with the control group (P<0.05). In terms of inflammatory mediators, the levels of IL-6, IL-8, LTB4 in serum did not change significantly (P>0.05) in two groups before and after treatment;IL-6, IL-8, LTB4 levels in the sputum supernatant of the therapy group were lower than those before treatment (P<0.05), with statistical significance compared with the control group (P<0.05). Conclusion Kechuanning capsules have an obvious inhibitory effect on airway inflammatory cells in patients with stable COPD as well as the release of inflammatory mediators.